Verve Therapeutics
Kallanthottathil G. Rajeev, PhD, serves as Senior Vice President of Chemistry at Verve Therapeutics since September 2018, previously holding the position of Vice President in CMC. At Alnylam Pharmaceuticals from June 2003 to May 2018, Rajeev was a pioneering chemist who led Medicinal Chemistry and played a key role in developing the GalNAc conjugate platform for siRNA delivery, contributing to the success of oligonucleotide therapeutics in clinical trials. Prior to Alnylam, Rajeev worked as a Senior Scientist at Ionis Pharmaceuticals, focusing on high-affinity base modifications and antisense applications, and as a Postdoctoral Fellow at the University of Utah, designing polynucleotides and nucleoside analogues. Rajeev earned a PhD in Chemistry from the National Chemical Laboratory in Pune, India.
This person is not in any offices
Verve Therapeutics
59 followers
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.